I have a more moderate take. I think it is likely that ivermectin will show some therapeutic benefit against death and hospitalization, but well below the efficacy of vaccination.
If so, I think there will be interesting reactions when the NIH Activ-6 trial reads out as the American public tries to digest this. Even low double digit efficacy will mean that slow implementation and pushback will have cost 10's to 100's of thousands of American lives.
In the hypothetical where it is demonstrated to be effective, I don't think it is ethical to suppress the use of one effective treatment to incentivize uptake of another (vaccination). That is to say, we shouldn't deny treatment with an effective treatment or post exposure prophylatic because it might embolden other people to forgo an earlier intervention (vaccination).
Your supply objection is a valid concern, but not absolute. I agree populations with parasites should get first priority if their relative benefit is greater. That said, there is additional manufacturing capacity and the ability to easily expand it. If you say excess supply cannot be used, this is the same as your argument above.
Might it have anything to do with the recovery rate of patients treated by frontline doctors who prescribe it (amongst other medicines), their patients are staying off ventilators and not, you know, dying? That's a huge observation and should be incorporated into the body of clinical medicine, without politics involved.